Track Biocon Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: -0.63 %
Low
409.0
High
421.6
1 Month returns: -5.59 %
Low
408.6
High
442.5
1 Year returns: 13.90 %
Low
337.0
High
447.1
3 Year CAGR: 16.37 %
Low
217.5
High
447.1
5 Year CAGR: 3.18 %
Low
191.6
High
447.1
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Biocon Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Biocon Ltd. Shareholding Pattern
Quarterly breakdown of Biocon Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Biocon Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Biocon Ltd.?
The current share price of Biocon Ltd. is ₹ 409.40 as of 24 Aug 2026.
What is the market capitalisation of Biocon Ltd.?
The market capitalisation of Biocon Ltd. stands at ₹ 66,684.20 Cr.
What is the PE ratio of Biocon Ltd.?
The Price-to-Earnings (PE) ratio of Biocon Ltd. is 134.63 as of the latest trailing twelve months data.
What is the ROE and ROCE of Biocon Ltd.?
Biocon Ltd. has a Return on Equity (ROE) of 1.39% and a Return on Capital Employed (ROCE) of 3.45% as per the latest financial reports.
What is the 52-week high and low of Biocon Ltd.?
The 52-week high of Biocon Ltd. is - and the 52-week low is -.
What is the dividend yield of Biocon Ltd.?
The dividend yield of Biocon Ltd. is 0.12% based on the current market price.
What is the FII and DII holding in Biocon Ltd.?
Foreign Institutional Investors (FII) hold 8.14%, Domestic Institutional Investors (DII) hold 21.95% and retail/public investors hold 17.65% of Biocon Ltd. shares.
What sector does Biocon Ltd. belong to?
Biocon Ltd. operates in the Healthcare sector. 43.75% of analysts have a Buy or Strong Buy rating on Biocon Ltd. with a consensus target price of ₹ 425.00, implying 3.81% upside from current levels.
What is the beta of Biocon Ltd.?
The beta of Biocon Ltd. is 0.64, indicating its price volatility relative to the broader market. Over the past 1 year, Biocon Ltd. has delivered an absolute return of 13.96%.
What is the RSI of Biocon Ltd.?
The 14-day Relative Strength Index (RSI) of Biocon Ltd. is 39.86, placing it approaching oversold territory. An RSI above 70 is considered overbought and below 30 is considered oversold.
Stock Analysis
Fundamental analysis overview of Biocon Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Strong price momentum
Price Momentum score of 78.2 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
78.2 / 100
Low and declining Debt to Equity
The company has low Debt to Equity of 0.45 as on 30 Jun 2026 and Debt to Equity decreased by 0.4 in the last 1 year
What is Debt to Equity?
Consistently pays dividend
The company has not missed dividend payments once in the last 4 financial years
What is Dividend streak?
Negative
Expensive and at a premium to industry median P/E
PE TTM of 134.63 indicates that the stock is expensive on a standalone basis and is at a 340.4% premium to industry median P/E
What is P/E Ratio?
Median: 30.57
Value 134.63
-0.85775.12
Analysts have been downgrading forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has decreased by -17.57% in the last 3 months, indicating weak earnings momentum
What is Earnings upgrade (3M)?
Low and declining ROE
The company reported low ROE of 1.39% for 12-month ended 30 Jun 2026 and ROE declined by -350 bps from 1 year ago
What is ROE (FY)?
Low but stable operating margin
The company reported low operating margin of 8.59% for 12-month ended 30 Jun 2026 and operating margin declined marginally by -110 bps from 1 year ago
What is Operating profit margin?
Low revenue growth and in line with median growth of industry
The company delivered low revenue growth of 9.83% for 12-month ended 30 Jun 2026 and the growth was 0.76 percentage points lower than median growth of industry
What is Sales growth (1Y)?
Median: 10.59
Value 9.83
-99.6111701.8
Low EPS growth and in line with median growth of industry
The company delivered low EPS growth of 5.23% for 12-month ended 30 Jun 2026 and the growth was 1.97 percentage points lower than median growth of industry
What is EPS growth (1Y)?
Low dividend yield
The company has a low dividend yield of 0.12%
What is Dividend yield?
Neutral
Company's earnings are of moderate quality
Earnings quality score of 68.4 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
68.4 / 100
No red flags found!
No significant red flags found in the stock.
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Company Profile
Overview of Biocon Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Biocon Limited is an India-based biopharmaceutical company, engaged in the manufacture of biotechnology products and research services. The Company is in the business of manufacturing active pharmaceutical ingredients (APIs) and formulations, including biosimilar drugs for diabetics, oncology and autoimmune diseases. The Company’s segment includes Generics, Biosimilars, Novel Biologics and Research Services. It focuses on three key therapeutic areas - Oncology, Diabetes, and Immunology. Its APIs portfolio includes cardiovascular, anti-diabetics, immunosuppressants, and specialty molecules. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. Its APIs manufacturing facilities with capabilities in microbial fermentation, downstream process, including chromatographic purification, chemical synthesis, peptide synthesis and Highly Potent APIs (HPAPIs). It has over five facilities in Bangalore, Hyderabad and Visakhapatnam in India.
Biocon Limited is an India-based biopharmaceutical company, engaged in the manufacture of biotechnology products and research services. The Company is in the business of manufacturing active pharmaceutical ingredients (APIs) and formulations, including biosimilar drugs for diabetics, oncology and au...
Key personnel
Mr. Kedar Narayan Upadhye
Chief Financial Officer
Mr. Rajesh Umakant Shanoy
Compliance Officer, Company Secretary
Mr. Akhilesh Nand
Head - Governance, Risk and Compliance
Mr. Saurabh Paliwal
Head - Investor Relations
Mr. Saurabh Paliwal
Head - Investor Relations
Mr. Saurabh Paliwal
Head - Investor Relations
Ms. Kiran Mazumdar-ShawD
Executive Chairperson of the Board
Mr. Shreehas Pradeep TambeD
Chief Executive Officer, Managing Director, Additional Director